Better Late Than Never: Novavax Submits COVID-19 Vaccine to FDA

It’s unclear whether the vaccine will be used in the U.S., as the country has relied heavily on mRNA shots from Pfizer and Moderna. Despite delays in submitting to the FDA, Novavax did secure conditional marketing authorization in Europe and an emergency use listing from the World Health Organization and in Indonesia and the Philippines. A statement from the company’s CEO noted that they are working with officials “to develop a plan which includes doses, manufacturing, timing and ongoing clinical trial research for boosters and pediatrics to support their pandemic response.